Cementless Acetabular Components Implanted with a High Hip Center in Total Hip Arthroplasty for Crowe II and III Hip Dysplasia

May 24, 2012

Institutional Review Board, Hospital for Special Surgery

The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.

For further information, see Understanding Clinical Trials/Research Studies.

Principal Investigator

Chitranjan S. Ranawat MD

Co-Investigators

Amar S. Ranawat MD
Danyal H. Nawabi MD
Matin Lendhey

Summary

50 patients. Minimum 10 year follow-up.

Inclusion/Exclusion Criteria

Inclusion:
Age 18-80 years, Crowe II and II dysplasia of the Hip, THA with a high hip center

Exclusion:
Revision THA for dysplasia, Crowe I and IV dysplasia

 

Contact Information

Chitranjan S. Ranawat MD
RanawatC@hss.edu
646.797.8700